Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1980 2
1981 13
1982 18
1983 18
1984 26
1985 28
1986 31
1987 28
1988 44
1989 35
1990 31
1991 50
1992 34
1993 46
1994 36
1995 43
1996 30
1997 27
1998 28
1999 22
2000 24
2001 20
2002 18
2003 54
2004 65
2005 78
2006 96
2007 88
2008 89
2009 89
2010 120
2011 165
2012 156
2013 158
2014 166
2015 195
2016 194
2017 211
2018 186
2019 218
2020 217
2021 233
2022 201
2023 180
2024 190
2025 269
2026 50

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,851 results

Results by year

Filters applied: . Clear all
Page 1
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA. Leder BZ, et al. Lancet. 2015 Sep 19;386(9999):1147-55. doi: 10.1016/S0140-6736(15)61120-5. Epub 2015 Jul 2. Lancet. 2015. PMID: 26144908 Free PMC article. Clinical Trial.
In DATA-Switch, women originally assigned to teriparatide received denosumab (teriparatide to denosumab group), those originally assigned to denosumab received teriparatide (denosumab to teriparatide group), and those originally assigned to both receiv …
In DATA-Switch, women originally assigned to teriparatide received denosumab (teriparatide to denosumab group), those original …
Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials.
Li M, Ge Z, Zhang B, Sun L, Wang Z, Zou T, Chen Q. Li M, et al. Arch Osteoporos. 2024 Sep 23;19(1):89. doi: 10.1007/s11657-024-01447-7. Arch Osteoporos. 2024. PMID: 39312040 Free PMC article.
Furthermore, teriparatide and denosumab did not increase the incidence of adverse events (teriparatide vs. bisphosphonates, RR 0.92, 95% CI (0.79, 1.08), P = 0.32; denosumab vs. bisphosphonates, RR 0.98, 95% CI (0.95, 1.02), P = 0.37). CONCLUSIONS: Teriparatide …
Furthermore, teriparatide and denosumab did not increase the incidence of adverse events (teriparatide vs. bisphosphonates, RR …
Teriparatide.
Berg C, Neumeyer K, Kirkpatrick P. Berg C, et al. Nat Rev Drug Discov. 2003 Apr;2(4):257-8. doi: 10.1038/nrd1068. Nat Rev Drug Discov. 2003. PMID: 12680372 No abstract available.
Change in spinal bone mineral density as estimated by Hounsfield units following osteoporosis treatment with romosozumab, teriparatide, denosumab, and alendronate: an analysis of 318 patients.
Mikula AL, Lakomkin N, Hamouda AM, Everson MC, Pennington Z, Kumar R, Pinter ZW, Martini ML, Bydon M, Kennel KA, Baffour F, Nassr A, Freedman B, Sebastian AS, Abode-Iyamah K, Anderson PA, Fogelson JL, Elder BD. Mikula AL, et al. J Neurosurg Spine. 2024 Jul 5;41(3):309-315. doi: 10.3171/2024.4.SPINE2424. Print 2024 Sep 1. J Neurosurg Spine. 2024. PMID: 38968619
METHODS: Spine and nonspine surgery patients were retrospectively identified who had been treated with romosozumab for 3 to 12 months, teriparatide for 3 to 12 months, teriparatide for > 12 months, denosumab for > 12 months, or alendronate for > 12 months. …
METHODS: Spine and nonspine surgery patients were retrospectively identified who had been treated with romosozumab for 3 to 12 months, te …
Teriparatide: a review.
Quattrocchi E, Kourlas H. Quattrocchi E, et al. Clin Ther. 2004 Jun;26(6):841-54. doi: 10.1016/s0149-2918(04)90128-2. Clin Ther. 2004. PMID: 15262455 Review.
CONCLUSIONS: Teriparatide has been shown clinically to improve BMD and BMC in postmenopausal women and in men. ...In 1 study, mild hypercalcemia was seen most often 4 to 6 hours after SC injection of teriparatide before returning to normal. Urinary calcium was obser …
CONCLUSIONS: Teriparatide has been shown clinically to improve BMD and BMC in postmenopausal women and in men. ...In 1 study, mild hy …
Latest on Anabolic Agents for Osteoporosis Treatment.
di Filippo L, Rosen CJ. di Filippo L, et al. Endocrinol Metab Clin North Am. 2024 Dec;53(4):513-523. doi: 10.1016/j.ecl.2024.08.003. Epub 2024 Sep 26. Endocrinol Metab Clin North Am. 2024. PMID: 39448133 Review.
These drugs include PTH-Related Analogues, teriparatide and abaloparatide, and the anti-sclerostin agent romosozumab, this latter drug currently approved only in female patients. Their efficacies in preventing fragility fractures are widely demonstrated and their potential …
These drugs include PTH-Related Analogues, teriparatide and abaloparatide, and the anti-sclerostin agent romosozumab, this latter dru …
Polypharmacy in Osteoporosis Treatment.
McConnell M, Shieh A. McConnell M, et al. Clin Geriatr Med. 2022 Nov;38(4):715-726. doi: 10.1016/j.cger.2022.05.011. Epub 2022 Sep 13. Clin Geriatr Med. 2022. PMID: 36210087 Review.
Treatments for osteoporosis include antiresorptive (alendronate, risedronate, zoledronic acid, ibandronate, denosumab) and osteoanabolic (teriparatide, abaloparatide, romosozumab) agents. Polypharmacy is associated with worse adherence to pharmacologic therapy. ...
Treatments for osteoporosis include antiresorptive (alendronate, risedronate, zoledronic acid, ibandronate, denosumab) and osteoanabolic ( …
Teriparatide-induced atrial tachycardia.
Ziffra JB Jr, Olshansky B. Ziffra JB Jr, et al. BMJ Case Rep. 2018 Feb 27;2018:bcr2017223035. doi: 10.1136/bcr-2017-223035. BMJ Case Rep. 2018. PMID: 29487102 Free PMC article.
She had been started on the injectable medication teriparatide (Forteo) and since then she had an increase in her symptoms. She was found to have intermittent atrial tachycardia with 1:1 conduction and occasional atrioventricular block transiently, coinciding with her inje …
She had been started on the injectable medication teriparatide (Forteo) and since then she had an increase in her symptoms. She was f …
Pharmacist-run teriparatide clinic.
Stroup J, Kane MP, Busch RS. Stroup J, et al. Am J Health Syst Pharm. 2003 Nov 1;60(21):2247-9. doi: 10.1093/ajhp/60.21.2247. Am J Health Syst Pharm. 2003. PMID: 14619118 No abstract available.
Teriparatide for severe osteoporosis.
Cappuzzo KA, Delafuente JC. Cappuzzo KA, et al. Ann Pharmacother. 2004 Feb;38(2):294-302. doi: 10.1345/aph.1D353. Epub 2003 Dec 30. Ann Pharmacother. 2004. PMID: 14742769 Review.
Common adverse effects noted with teriparatide use were nausea, headache, dizziness, and arthralgias. An increased incidence of osteosarcoma in rats during preclinical trials with teriparatide led to a black box warning for the drug. CONCLUSIONS: Teriparatide …
Common adverse effects noted with teriparatide use were nausea, headache, dizziness, and arthralgias. An increased incidence of osteo …
3,851 results